- Home
- CYCN vs APLM Comparison
CYCN vs APLM Comparison
Compare CYCN & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYCN
- APLM
- Stock Information
- Founded
- CYCN 2018
- APLM 2016
- Country
- CYCN United States
- APLM United States
- Employees
- CYCN N/A
- APLM N/A
- Industry
- CYCN Biotechnology: Pharmaceutical Preparations
- APLM Blank Checks
- Sector
- CYCN Health Care
- APLM Finance
- Exchange
- CYCN Nasdaq
- APLM Nasdaq
- Market Cap
- CYCN 6.5M
- APLM 6.9M
- IPO Year
- CYCN N/A
- APLM N/A
- Fundamental
- Price
- CYCN $2.81
- APLM $6.41
- Analyst Decision
- CYCN
- APLM
- Analyst Count
- CYCN 0
- APLM 0
- Target Price
- CYCN N/A
- APLM N/A
- AVG Volume (30 Days)
- CYCN 21.8K
- APLM 4.6K
- Earning Date
- CYCN 08-06-2025
- APLM 08-13-2025
- Dividend Yield
- CYCN N/A
- APLM N/A
- EPS Growth
- CYCN N/A
- APLM N/A
- EPS
- CYCN N/A
- APLM N/A
- Revenue
- CYCN $2,081,000.00
- APLM $198,000.00
- Revenue This Year
- CYCN N/A
- APLM $415.15
- Revenue Next Year
- CYCN N/A
- APLM N/A
- P/E Ratio
- CYCN N/A
- APLM N/A
- Revenue Growth
- CYCN N/A
- APLM N/A
- 52 Week Low
- CYCN $1.27
- APLM $4.47
- 52 Week High
- CYCN $9.47
- APLM $35.98
- Technical
- Relative Strength Index (RSI)
- CYCN 41.24
- APLM 51.61
- Support Level
- CYCN $3.02
- APLM $5.34
- Resistance Level
- CYCN $3.16
- APLM $6.70
- Average True Range (ATR)
- CYCN 0.21
- APLM 0.52
- MACD
- CYCN -0.03
- APLM -0.03
- Stochastic Oscillator
- CYCN 16.26
- APLM 67.65
About CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.
About APLM Apollomics Inc.
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.